GB862376A - Sustained release pharmaceutical tablet - Google Patents

Sustained release pharmaceutical tablet

Info

Publication number
GB862376A
GB862376A GB31614/58A GB3161458A GB862376A GB 862376 A GB862376 A GB 862376A GB 31614/58 A GB31614/58 A GB 31614/58A GB 3161458 A GB3161458 A GB 3161458A GB 862376 A GB862376 A GB 862376A
Authority
GB
United Kingdom
Prior art keywords
proportion
weight
fatty acid
sustained release
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB31614/58A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Charles Pfizer and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc, Charles Pfizer and Co Inc filed Critical Pfizer Inc
Publication of GB862376A publication Critical patent/GB862376A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

A sustained release tablet comprises compressed granules containing an active medicament dispersed in a dried aluminium hydroxide gel which are coated with a water-soluble binder. An inert filler, a solid fatty acid having at least 10 carbon atoms and an emulsifying agent for said acid may be included. The tablet slowly disintegrates as it passes through the gastro-intestinal tract, the rate of disintegration being controlled by the proportion of aluminium hydroxide gel, which may range from 10 to 30% by weight and by inclusion of a saturated fatty acid having at least 10 carbon atoms in the proportion of 10 to 30% by weight. The binder may be, for example, a sugar syrup, a gum, carboxymethyl cellulose in the proportion of 10 to 20% by weight; the inert filler may be, for example, di- or tri-calcium phosphate, kaolin or calcium sulphate. The emulsifying agent, advantageously added in the proportion of 3 to 10% by weight when a fatty acid is included, may be sodium taurocholate or sodium glycocholate. Examples of the composition and preparation of various tablets are given which show disintegration times in synthetic gastric juice ranging from 9 to 29 hours.
GB31614/58A 1957-10-10 1958-10-03 Sustained release pharmaceutical tablet Expired GB862376A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US862376XA 1957-10-10 1957-10-10

Publications (1)

Publication Number Publication Date
GB862376A true GB862376A (en) 1961-03-08

Family

ID=22197189

Family Applications (1)

Application Number Title Priority Date Filing Date
GB31614/58A Expired GB862376A (en) 1957-10-10 1958-10-03 Sustained release pharmaceutical tablet

Country Status (1)

Country Link
GB (1) GB862376A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2209585A1 (en) * 1972-12-09 1974-07-05 Hoechst Ag
US4163777A (en) * 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
FR2470599A1 (en) * 1979-12-07 1981-06-12 Panoz Donald IMPROVEMENTS IN PROCESSES FOR THE PREPARATION OF GALENIC SHAPES WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED
US4853230A (en) * 1986-04-30 1989-08-01 Aktiebolaget Hassle Pharmaceutical formulations of acid labile substances for oral use
WO1994007469A1 (en) * 1992-09-25 1994-04-14 Dynagen, Inc. An immunobooster for delayed release of immunogen
US6576258B1 (en) 1997-07-14 2003-06-10 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Pharmaceutical formulation with controlled release of active substances
WO2013163738A1 (en) * 2012-04-30 2013-11-07 Mircea-Alexandru Mateescu Complex containing carboxyl substituted starch and lipid for delayed delivery of active ingredients

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2209585A1 (en) * 1972-12-09 1974-07-05 Hoechst Ag
US4163777A (en) * 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
FR2470599A1 (en) * 1979-12-07 1981-06-12 Panoz Donald IMPROVEMENTS IN PROCESSES FOR THE PREPARATION OF GALENIC SHAPES WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED
WO1981001652A1 (en) * 1979-12-07 1981-06-25 D Panoz Improvements to methods for preparing galenical preparation with delayed action and programmed release and galenical preparations for drugs obtained thereby
US5051262A (en) * 1979-12-07 1991-09-24 Elan Corp., P.L.C. Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
US4853230A (en) * 1986-04-30 1989-08-01 Aktiebolaget Hassle Pharmaceutical formulations of acid labile substances for oral use
WO1994007469A1 (en) * 1992-09-25 1994-04-14 Dynagen, Inc. An immunobooster for delayed release of immunogen
US5656298A (en) * 1992-09-25 1997-08-12 Dynagen, Inc. Immunobooster for delayed release of immunogen
US6576258B1 (en) 1997-07-14 2003-06-10 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Pharmaceutical formulation with controlled release of active substances
WO2013163738A1 (en) * 2012-04-30 2013-11-07 Mircea-Alexandru Mateescu Complex containing carboxyl substituted starch and lipid for delayed delivery of active ingredients
US9220699B2 (en) 2012-04-30 2015-12-29 Karici Diagnostics Inc. Complex containing carboxyl substituted starch and lipid for delayed delivery of active ingredients

Similar Documents

Publication Publication Date Title
GB1471564A (en) Direct compression tabletting composition and tablets produced therefrom
IL42232A (en) Dry medicines for oral administration
ES403435A1 (en) Slow release pharmaceutical compositions
SE7502725L (en)
GB1430684A (en) Prolonged release lozenges
US3632778A (en) Tablets containing l-dopa
GB862376A (en) Sustained release pharmaceutical tablet
DE1907546C3 (en) Rapidly disintegrating solid dosage units
ES370058A1 (en) Antibiotic compositions
GB934089A (en) Improvements in or relating to sustained release medicaments
ES393211A1 (en) Preparation of redispersible hydrophobic starch derivatives
GB1464200A (en) Pharmaceutical composition
GB1209093A (en) Pharmaceutical preparation
ES395533A1 (en) Sustained released pharmaceutical compositions
ES8106835A1 (en) Process for the preparation of gastric acid neutralizing agents and gastric acid neutralizing agents.
JPS6320409B2 (en)
GB1296944A (en)
EP0073428A3 (en) Medicinal preparations for glycoside-hydrolase inhibitors
GB1266647A (en) Starch liquefaction process
FR2108032A1 (en) Prolonged progressively released oral medicament - comprises a solid excipient and cellulose dicarboxylic acid binder
ES380779A1 (en) Procedure for the preparation of anticidal compositions. (Machine-translation by Google Translate, not legally binding)
US3740432A (en) Vitamin complexes of niacinamide,riboflavin and sodium ascorbate
US2864744A (en) Penicillin in solid dosage unit form
ES8300468A1 (en) Non-bleeding chewable tablets having high lipid content.
JPH01319416A (en) Tablet binder capable of controlling release